Lugner, M., Sattar, N., Miftaraj, M., Ekelund, J., Franzén, S., Svensson, A., & Eliasson, B. (2021). Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: Nationwide observational study. Cardiovasc Diabetol.
Citação norma ChicagoLugner, Moa, Naveed Sattar, Mervete Miftaraj, Jan Ekelund, Stefan Franzén, Ann-Marie Svensson, and Björn Eliasson. "Cardiorenal and Other Diabetes Related Outcomes With SGLT-2 Inhibitors Compared to GLP-1 Receptor Agonists in Type 2 Diabetes: Nationwide Observational Study." Cardiovasc Diabetol 2021.
Citação norma MLALugner, Moa, et al. "Cardiorenal and Other Diabetes Related Outcomes With SGLT-2 Inhibitors Compared to GLP-1 Receptor Agonists in Type 2 Diabetes: Nationwide Observational Study." Cardiovasc Diabetol 2021.